Antinociceptive and antidiarrheal effects of pioglitazone in a rat model of diarrhoea-predominant irritable bowel syndrome: Role of nitric oxide

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 2, 2014, Pages 118-126

  Paragomi, Pedram ^a,b   Rahimian, Reza ^b,c   Kazemi, Mohammad Hossein ^b   Gharedaghi, Mohammad Hadi ^b,c   Khalifeh Soltani, Amin ^b   Azary, Saeedeh ^b   Javidan, Abbas Norouzi ^c   Moradi, Kamran ^a   Sakuma, Stephen ^d   Dehpour, Ahmad Reza ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antinociception; Irritable bowel syndrome; Nitric oxide; Pioglitazone; Rats

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ACETIC ACID; ARGININE; DIMETHYL SULFOXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIARRHEAL ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEFECATION; DIARRHEA; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FECES ANALYSIS; IRRITABLE COLON; MALE; NONHUMAN; PAIN THRESHOLD; RAT;

ANTINOCICEPTION; IRRITABLE BOWEL SYNDROME; NITRIC OXIDE; PIOGLITAZONE; RATS;

ANALGESICS; ANIMALS; ANTIDIARRHEALS; DIARRHEA; DISEASE MODELS, ANIMAL; IRRITABLE BOWEL SYNDROME; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PAIN THRESHOLD; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84897548010     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12188     Document Type: Article

References (59)

1. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012; 345: e5836.
2. Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig. Liver Dis. 2007; 39: 201-15.
3. Hughes PA, Brierley SM, Blackshaw LA. Post-inflammatory modification of colonic afferent mechanosensitivity. Clin. Exp. Pharmacol. Physiol. 2009; 36: 1034-40.
4. Creed F, Ratcliffe J, Fernandez L et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann. Intern. Med. 2001; 134: 860-8.
5. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
6. Desvergne B, IJpenberg A, Devchand PR, Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J. Steroid Biochem. Mol. Biol. 1998; 65: 65-74.
7. Park SW, Yi JH, Miranpuri G et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 2007; 320: 1002-12.
8. Jain V, Jaggi AS, Singh N. Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol. Res. 2009; 59: 385-92.
9. Qiang X, Satoh J, Sagara M et al. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998; 41: 1321-6.
10. Yamagishi S, Ogasawara S, Mizukami H et al. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J. Neurochem. 2008; 104: 491-9.
11. Ignarro LJ. Heme-dependent activation of guanylate cyclase by nitric oxide: A novel signal transduction mechanism. Blood Vessels 1991; 28: 67-73.
12. Chung E, Burke B, Bieber AJ, Doss JC, Ohgami Y, Quock RM. Dynorphin-mediated antinociceptive effects of l-arginine and SIN-1 (an NO donor) in mice. Brain Res. Bull. 2006; 70: 245-50.
13. Durate ID, Lorenzetti BB, Ferreira SH. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur. J. Pharmacol. 1990; 186: 289-93.
14. Javanmardi K, Parviz M, Sadr SS, Keshavarz M, Minaii B, Dehpour AR. Involvement of N-methyl-d-aspartate receptors and nitric oxide in the rostral ventromedial medulla in modulating morphine pain-inhibitory signals from the periaqueductal grey matter in rats. Clin. Exp. Pharmacol. Physiol. 2005; 32: 585-9.
15. Reis GM, Pacheco D, Perez AC, Klein A, Ramos MA, Duarte ID. Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci. 2009; 85: 351-6.
16. Dai C, Guandalini S, Zhao DH, Jiang M. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: A possible action through nitric oxide pathway and enhance barrier function. Mol. Cell. Biochem. 2012; 362: 43-53.
17. ATP channels. J. Pharmacol. Exp. Ther. 2006; 316: 325-35.
18. Fritz E, Hammer J, Schmidt B, Eherer AJ, Hammer HF. Stimulation of the nitric oxide-guanosine 3′, 5′-cyclic monophosphate pathway by sildenafil. Effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. Am. J. Gastroenterol. 2003; 98: 2253-60.
19. Goncalves de Medeiros M, de Oliveira RB, dos Santos AA et al. The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome. Aliment. Pharmacol. Ther. 2012; 35: 577-86.
20. Konturek PC, Brzozowski T, Kania J et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur. J. Pharmacol. 2003; 472: 213-20.
21. Ye Y, Lin Y, Manickavasagam S, Perez-Polo JR, Tieu BC, Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am. J. Physiol. Heart Circ. Physiol. 2008; 295: H2436-46.
22. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51 (Suppl. 1): I-41.
23. Mangel AW, Hicks GA. Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: A review. Clin. Exp. Gastroenterol. 2012; 5: 1-10.
24. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol. 2002; 35: S58-67.
25. Alzamendi A, Giovambattista A, Garcia ME, Rebolledo OR, Gagliardino JJ, Spinedi E. Effect of pioglitazone on the fructose-induced abdominal adipose tissue dysfunction. PPAR Res. 2012; 2012: 259093.
26. Gupta R, Gupta LK. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. Pharmacol. Biochem. Behav. 2012; 102: 184-90.
27. Werner C, Gensch C, Poss J, Haendeler J, Bohm M, Laufs U. Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis. Atherosclerosis 2011; 216: 23-34.
28. La JH, Kim TW, Sung TS, Kang JW, Kim HJ, Yang IS. Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis. World J. Gastroenterol. 2003; 9: 2791-5.
29. Shamshiri H, Paragomi P, Paydar MJ et al. Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: The role of nitric oxide pathway. J. Gastroenterol. Hepatol. 2009; 24: 672-80.
30. Xu JR, Luo JY, Shang L, Kong WM. Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models. Chin. J. Dig. Dis. 2006; 7: 89-96.
31. Zhu WL, Li Y, Wei HF et al. Effect of electro-acupuncture at different acupoints on neuropeptide and somatostatin in rat brain with irritable bowel syndrome. Chin. J. Integr. Med. 2012; 18: 288-92.
32. Drossman DA. Review article: An integrated approach to the irritable bowel syndrome. Aliment. Pharmacol. Ther. 1999; 13(Suppl. 2): 3-14.
33. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000; 119: 1276-85.
34. Coker RK, Laurent GJ. Pulmonary fibrosis: Cytokines in the balance. Eur. Respir. J. 1998; 11: 1218-21.
35. Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J. Dig. Dis. 2007; 8: 82-8.
36. Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J. Pharmacol. Sci. 2008; 108: 341-7.
37. Jia H, Zhu S, Ji Q et al. Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain. Exp. Clin. Psychopharmacol. 2010; 18: 359-65.
38. Festuccia WT, Oztezcan S, Laplante M et al. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 2008; 149: 2121-30.
39. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 2006; 199: 265-73.
40. Risner ME, Saunders AM, Altman JF et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006; 6: 246-54.
41. Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur. J. Pharmacol. 2007; 561: 194-201.
42. Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK. Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 2010; 58: 337-45.
43. Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J. Pain 2008; 9: 639-49.
44. Konturek PC, Brzozowski T, Burnat G et al. Gastric ulcer healing and stress-lesion preventive properties of pioglitazone are attenuated in diabetic rats. J. Physiol. Pharmacol. 2010; 61: 429-36.
45. Lozano-Cuenca J, Castaneda-Hernandez G, Granados-Soto V. Peripheral and spinal mechanisms of antinociceptive action of lumiracoxib. Eur. J. Pharmacol. 2005; 513: 81-91.
46. Santodomingo-Garzon T, Cunha TM, Verri WA Jr et al. Atorvastatin inhibits inflammatory hypernociception. Br. J. Pharmacol. 2006; 149: 14-22.
47. 2-induced antinociception in rat temporomandibular joint. Neuroscience 2009; 163: 1211-9.
48. 2 inhibits inflammatory hypernociception: Involvement of peripheral opioid receptor. J. Pharmacol. Exp. Ther. 2008; 324: 313-21.
49. Salzman AL. Nitric oxide in the gut. New Horiz. 1995; 3: 352-64.
50. Schirgi-Degen A, Beubler E. Significance of nitric oxide in the stimulation of intestinal fluid absorption in the rat jejunum in vivo. Br. J. Pharmacol. 1995; 114: 13-8.
51. Feinstein DL, Spagnolo A, Akar C et al. Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem. Pharmacol. 2005; 70: 177-88.
52. Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin. Exp. Pharmacol. Physiol. 2009; 36: 478-86.
53. Toriumi Y, Hiraoka M, Watanabe M, Yoshida M. Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase. FEBS Lett. 2003; 553: 419-22.
54. Li L, Gao PJ, Xi R et al. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism. Clin. Exp. Pharmacol. Physiol. 2008; 35: 1471-6.
55. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002; 82: 615-24.
56. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001; 7: 48-52.
57. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. USA 2003; 100: 6712-7.
58. Zou MH, Kirkpatrick SS, Davis BJ et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem. 2004; 279: 43-940-51
59. Quan C, Talley NJ, Jones MP, Howell S, Horowitz M. Gastrointestinal symptoms and glycemic control in diabetes mellitus: A longitudinal population study. Eur. J. Gastroenterol. Hepatol. 2008; 20: 888-97.